Critically, these compounds also enhance PARPi-mediated cell killing, target PARPi resistant cell lines and tumours resulting from loss of 53BP1 and Shieldin components and have been recently shown to potentiate radiotherapy (21,47). Here, TP53BP1 is linked to neoplasm.